Benefits of Akkermansia

Evidence-Based Benefits

• Gut barrier integrity — Akkermansia feeds on and stimulates production of mucin, the protective gel layer lining the intestinal wall, strengthening the gut barrier against endotoxins
• Metabolic health — a landmark 2019 RCT by Depommier et al. found pasteurized Akkermansia improved insulin sensitivity, reduced insulinemia, and decreased total plasma cholesterol in overweight/obese subjects
• GLP-1 pathway support — Akkermansia produces short-chain fatty acids and interacts with Toll-like receptor 2 (TLR2), which may indirectly support GLP-1 secretion from intestinal L-cells
• Body composition — preclinical and early clinical data suggest Akkermansia supplementation reduces fat mass gain and improves markers of metabolic syndrome
• Reduced systemic inflammation — by improving gut barrier function, Akkermansia reduces the translocation of lipopolysaccharide (LPS) into the bloodstream, lowering chronic low-grade inflammation

What the Research Says

Research on Akkermansia muciniphila is still early but compelling. The landmark 2019 proof-of-concept RCT by Depommier et al. in Nature Medicine (n=32) found that pasteurized Akkermansia improved insulin sensitivity, reduced insulinemia by 28%, and decreased total cholesterol and relevant blood markers in overweight/obese volunteers over 3 months. Notably, pasteurized bacteria outperformed live bacteria, likely because the outer membrane protein Amuc_1100 — responsible for many of the metabolic benefits — is heat-stable and more bioavailable after pasteurization. Preclinical work in mice has consistently shown that Akkermansia supplementation prevents diet-induced obesity and improves gut barrier function. As of 2025, Akkermansia has received Novel Food approval from the European Food Safety Authority (EFSA), validating its safety profile for human consumption.

Related Conditions